Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10204303 | 0.88 | SMN1; SMN2 (0.34) | CA2CA9CA1CYP1A2CYP3A4 | |
| SCHEMBL568752 | 0.88 | GAA (0.33) | CA2CA9CA1CYP1A2CYP3A4 | |
| SCHEMBL25300943 | 0.84 | CYP1A2 (0.35) | CYP1A2CYP3A4CYP2D6TSHRKDM4E | |
| SCHEMBL10204617 | 0.84 | LMNA (0.31) | LMNA | |
| SCHEMBL30509978 | 0.81 | KDM4E (0.38) | TSHRKDM4EALDH1A1LMNAUSP2 | |
| SCHEMBL25252110 | 0.81 | KDM4E (0.38) | TSHRKDM4EALDH1A1LMNAUSP2 | |
| SCHEMBL26077236 | 0.80 | L3MBTL1 (0.32) | ALDH1A1L3MBTL1MAPTKMT2AMEN1 | |
| SCHEMBL20605048 | 0.80 | HTT (0.41) | CA2CA1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL14430286 | 0.79 | CA2 (0.42) | CA2CA9CA1TSHRKDM4E | |
| SCHEMBL10204294 | 0.78 | CYP1A2 (0.34) | CA2CA9CA1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110275637-A1 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2011-11-10 | — | — | US | disclosed |
| EP-2313096-A1 | NEW COMPOUNDS V | AstraZeneca AB (Publ) (SE) | 2011-04-27 | — | — | EP | disclosed |
| WO-2009147211-A1 | NEW COMPOUNDS V | BIOVITRUM AB (PUBL) (SE) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275637-A1 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | ADIPOR2, GPR119, ADIPOR1 | CA2 3609/4885CA9 4883/4885CA1 4806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.